Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 17, Issue 30, Pages 3341-3347Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161211797904163
Keywords
Diabetes mellitus; mesenchymal stromal cells; endothelial dysfunction; fibrosis
Categories
Funding
- Berlin-Brandenburg Center for Regenerative Therapies - BCRT (Bundesministerium fur Bildung und Forschung) [0313911]
- European 7th Framework
Ask authors/readers for more resources
Diabetic cardiopathy includes a specific cardiomyopathy, which occurs in the absence of coronary heart disease under diabetes mellitus. Hallmarks of diabetic cardiomyopathy are besides others, interstitial inflammation, cardiac oxidative stress, interstitial and perivascular fibrosis, cardiac apoptosis, intramyocardial microangiopathy, endothelial dysfunction, abnormal intracellular Ca2+-handling, cardiomyocyte hypertrophy, and impaired cardiac stem cells. Since mesenchymal stromal cells have been shown to have anti-diabetic as well as cardioprotective features, we summarize in this review how they can indirectly affect diabetic cardiomyopathy via their influence on the metabolic trigger hyperglycemia, and how they can directly influence the cardiac cellular consequences typical for diabetic cardiomyopathy via their immunomodulatory, anti-oxidative, anti-fibrotic, anti-apoptotic, pro-angiogenic, and endothelial-protective features, and their ability to activate cardiac progenitor cells. Furthermore, the dysfunctionality of (bone marrow-derived) mesenchymal stromal cells under diabetes mellitus and potential strategies to overcome this impairment in cell functionality are outlined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available